CL2021000882A1 - Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. - Google Patents

Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.

Info

Publication number
CL2021000882A1
CL2021000882A1 CL2021000882A CL2021000882A CL2021000882A1 CL 2021000882 A1 CL2021000882 A1 CL 2021000882A1 CL 2021000882 A CL2021000882 A CL 2021000882A CL 2021000882 A CL2021000882 A CL 2021000882A CL 2021000882 A1 CL2021000882 A1 CL 2021000882A1
Authority
CL
Chile
Prior art keywords
vomiting
chemotherapy
nausea
induced
formulations
Prior art date
Application number
CL2021000882A
Other languages
English (en)
Inventor
Catherine Jacobson
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of CL2021000882A1 publication Critical patent/CL2021000882A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona una formulación de cannabidiol y delta-9- tetrahidrocannabinol. La formulación es una forma de dosificación oral sólida. En algunas realizaciones, la formulación es una formulación liposomal oral. La presente invención también proporciona métodos para tratar náuseas y vómitos inducidos por quimioterapia mediante la administración de tales formulaciones a un paciente antes y/o después de que el paciente reciba el tratamiento de quimioterapia. Las náuseas y los vómitos inducidos por quimioterapia que están tratándose pueden comprender náuseas y vómitos agudos inducidos por quimioterapia, náuseas y vómitos tardíos inducidos por quimioterapia o ambos.
CL2021000882A 2018-10-10 2021-04-09 Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. CL2021000882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
CL2021000882A1 true CL2021000882A1 (es) 2021-08-27

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000882A CL2021000882A1 (es) 2018-10-10 2021-04-09 Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.

Country Status (12)

Country Link
US (1) US20200113847A1 (es)
EP (1) EP3863614A1 (es)
JP (1) JP2022502471A (es)
KR (1) KR20210116432A (es)
AU (1) AU2019357608A1 (es)
BR (1) BR112021006858A2 (es)
CA (1) CA3115985A1 (es)
CL (1) CL2021000882A1 (es)
CO (1) CO2021005797A2 (es)
MX (1) MX2021004138A (es)
PE (1) PE20211198A1 (es)
WO (1) WO2020077103A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232379A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof
MX2022014459A (es) * 2020-05-18 2023-02-27 Max Biology Co Ltd Composiciones de lipidos y polimeros y metodos de uso.
EP4203716A1 (en) * 2020-09-24 2023-07-05 Nicoventures Trading Limited Formulation
US20240252464A1 (en) * 2022-07-06 2024-08-01 Avantsar Sdn Bhd A self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
EP1706098A4 (en) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICRO-LAYER SYSTEMS FOR THE TRANSPORT OF LIPOPHILES AND BZW. HYDROPHOBIC COMPOUNDS
BRPI0610364A2 (pt) * 2005-05-13 2010-06-15 Unimed Pharmaceuticals Inc tratamento, com dronabinol, de náusea e vÈmito retardados induzidos por quimioterapia
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CA2929280A1 (en) * 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
CA3025208A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
US20180085308A1 (en) * 2016-09-27 2018-03-29 CannTab Therapeutics Limited Sustained release cannabinoid formulations
EP3525764A4 (en) * 2016-10-12 2020-05-13 Columbia Care LLC ORAL COMPOSITION OF EXTRACTED CANNABINOIDS AND METHOD FOR USE THEREOF
KR20190103302A (ko) * 2017-01-03 2019-09-04 리셉터 홀딩스, 인크. 의약 화합물 및 영양 보충제
CN110636834A (zh) * 2017-02-15 2019-12-31 分子浸剂有限公司 制剂
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
CA3119786A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
BR112020017023A2 (pt) * 2018-02-23 2021-03-02 Nicola Michael Spirtos terapêutica à base de cannabis e método de uso
CN112638369A (zh) * 2018-07-31 2021-04-09 奥斯卡恩集团控股有限公司 固体自乳化药物组合物

Also Published As

Publication number Publication date
JP2022502471A (ja) 2022-01-11
MX2021004138A (es) 2021-08-05
CO2021005797A2 (es) 2021-05-20
EP3863614A1 (en) 2021-08-18
BR112021006858A2 (pt) 2021-07-13
US20200113847A1 (en) 2020-04-16
AU2019357608A1 (en) 2021-05-27
CA3115985A1 (en) 2020-04-16
KR20210116432A (ko) 2021-09-27
WO2020077103A1 (en) 2020-04-16
PE20211198A1 (es) 2021-07-01

Similar Documents

Publication Publication Date Title
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2019003134A (es) Terapia de combinacion.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
CO2019007879A2 (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a